Wu YD, Yang KZ, Zhou DN, Gang YQ, Song XQ, Hu XH, Huang BY. Clinical observation of 125I-labeled anti-alpha fetoprotein antibody radioimmunotherapy in hepatocellular carcinoma. World J Gastroenterol 1997; 3(1): 43-46 [PMID: 27006585 DOI: 10.3748/wjg.v3.i1.43]
Corresponding Author of This Article
Dr. Ying-De Wu, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China
Article-Type of This Article
Original Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Ying-De Wu, Ke-Zeng Yang, You-Quan Gang, Xiang-Qun Song, Xiao-Hua Hu, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China
De-Nan Zhou, Guangxi Cancer Institute, Nanning, Guangxi Province, China
Ying-De Wu, male, born on February 10, 1936, Fu Sui County, Zhuang nationality, graduated from the Faculty of Medicine, Guangxi Medical University, professor and chief physician of the Department of Medical Oncology; former head of the Department of Cancer Prevention and Director of the Department of Chemotherapy. Since 1980 he has been engaged mainly in the study of targeted therapy for hepatocellular carcinoma, radiation therapy and tumor chemotherapy, hepatocellular carcinoma research at state and provincial level, and has 31 papers published. At present, he is the Director of the Department of Immunity, Cancer Institute, Secretary General of Guangxi Anticancer Association and Executive Editor of the Journal of Chinese Medical Abstract — Oncology.
Author contributions: All authors contributed equally to the work.
Supported by Grants from Guangxi Commission of Science and Technology Research Items, No.900226.
Correspondence to: Dr. Ying-De Wu, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China
Received: August 29, 1996 Revised: December 1, 1996 Accepted: December 30, 1996 Published online: March 15, 1997
Abstract
AIM: To observe the therapeutic effects and toxic side effects of 125I labeled horse anti-human alpha fetoprotein (AFP) polyclonal antibodies in immune targeted therapy against hepatocellular carcinoma (HCC).
METHODS: A modified chloramine-T method to produce nuclide 125I labeled horse anti-human AFP polyclonal antibodies was used to treat 22 cases of HCC. Drugs were administered by intravenous drip. The median dose of 125I in the whole group was 289.3 (100.3-708.9) MBq. In this series of 22 cases, 19 were evaluated. HCC cases of the same period treated by 131I anti AFP (A group), anti-cancer drugs and anti AFP conjugates (B group) and chemotherapy alone (C group) were used as controls.
RESULTS: The effective rate (CR + PR) was 31.6%, tumor shrinkage rate was 63.2% (12/19), AFP descending rate 64.7% (11/17) and 6 cases became AFP negative. The post treatment 1 year survival rate was 47.1% (8/17). Seven cases are still alive. Five cases survived 14.33 mo, showing good therapeutic tolerance and minimal toxic side effects.
CONCLUSION: The therapeutic effect in the treatment group was significantly better than that of the control groups. This may be due to the effect of the continuous radiation of the long half life 125I within the tumor cells.
